No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Pfizer Positioned for Growth: Buy Rating Affirmed Due to Operational Efficiency, Strategic Capital Allocation, and Undervaluation
Citigroup Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating
Goldman Sachs Ups Price Target on Pfizer to $27 From $25, Maintains Neutral Rating
Market Rally at Risk as Tariffs Damage Spreads. -2-
Morgan Stanley Lifts Price Target on Pfizer to $32 From $31, Keeps Equalweight Rating